Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
Launched by WAVE LIFE SCIENCES LTD. · Jul 20, 2017
Trial Information
Current as of June 29, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Prescreened with targeted SNP on the same allele as the pathogenic CAG expansion
- • Ambulatory, male or female patients aged ≥25 - ≤65 years
- • Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4
- • Early manifest HD, Stage I or Stage II based on UHDRS Total Functional Capacity Scores ≥7 and ≤13
- Key Exclusion Criteria:
- • Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years.
- • Received investigational drug or implantable device in prior 3 months or investigational oligonucleotide in prior 6 months or 5 half-lives of the oligonucleotide, whichever is longer
- • Clinically significant medical condition, unstable psychiatric symptoms, substance abuse, or pregnancy
- • Inability to undergo brain MRI
- • Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a biotechnology company focused on pioneering innovative therapies for genetic diseases through its proprietary RNA modulation platform. With a commitment to advancing precision medicine, Wave harnesses its expertise in drug development to create transformative treatments that address the underlying causes of diseases. The company is dedicated to improving patient outcomes by leveraging cutting-edge science and technology, and it actively engages in clinical trials to evaluate the safety and efficacy of its novel therapeutic candidates. Wave Life Sciences aims to be at the forefront of the biopharmaceutical industry, driving breakthroughs that have the potential to change the lives of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Edmonton, Alberta, Canada
Liverpool, , United Kingdom
Melbourne, Victoria, Australia
Paris, , France
Créteil, , France
Clayton, Victoria, Australia
Toronto, Ontario, Canada
Sidney, New South Wales, Australia
Herston, Queensland, Australia
Carlton, Victoria, Australia
Parkdale, Victoria, Australia
Perth, Western Australia, Australia
Montreal, Quebec, Canada
Aarhus, , Denmark
Odense, , Denmark
Muenster, , Germany
Gdańsk, , Poland
Warsaw, , Poland
Exeter, Devon, United Kingdom
Glasgow, Glasgow City, United Kingdom
Patients applied
Trial Officials
Medical Director, MD
Study Director
Wave Life Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials